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Fragile-X syndrome is caused by an unstable CGG trinucleotide repeat in the FMR1 gene at Xq27. Intermediate
alleles (51–200 repeats) can undergo expansion to the full mutation on transmission from mother to offspring. To
evaluate the effectiveness of a fragile-X carrier–screening program, we tested 14,334 Israeli women of child-bearing
age for fragile-X carrier status between 1992 and 2000. These women were either preconceptional or pregnant
and had no family history of mental retardation. All those found to be carriers of premutation or full-mutation
alleles were offered genetic counseling and also prenatal diagnosis, if applicable. We identified 207 carriers of an
allele with 150 repeats, representing a prevalence of 1:69. There were 127 carriers with 154 repeats, representing
a prevalence of 1:113. Three asymptomatic women carried the fully mutated allele. Among the premutation and
full-mutation carriers, 177 prenatal diagnoses were performed. Expansion occurred in 30 fetuses, 5 of which had
an expansion to the full mutation. On the basis of these results, the expected number of avoided patients born to
women identified as carriers, the cost of the test in this study (U.S. $100), and the cost of lifetime care for a mentally
retarded person (1$350,000), screening was calculated to be cost-effective. Because of the high prevalence of fragile-
X premutation or full-mutation alleles, even in the general population, and because of the cost-effectiveness of the
program, we recommend that screening to identify female carriers should be carried out on a wide scale.
Introduction
Fragile-X syndrome is an X-linked genetic syndrome
now recognized as the second leading identifiable cause
of mental retardation, after Down syndrome. Its fre-
quency in males is estimated to be ∼1:4,000 (Murray
et al. 1996; Turner et al. 1996). It is caused by an un-
stable CGG trinucleotide-repeat sequence mutation
found in the fragile-X mental retardation gene (FMR1
[MIM 309550]) at the chromosomal locus Xq27 (Kre-
mer et al. 1991; Oberle´ et al. 1991; Verkerk et al. 1991;
Yu et al. 1991). Routine clinical testing for mutations
in the FMR1 gene determines the trinucleotide-repeat
number and/or gene-methylation status, which are con-
stant in each individual, so that each person needs to
undergo the test only once. The following types of alleles
are observed: normal (6–50 CGG repeats, usually
29–30), premutation (or “intermediate”) (51–200 CGG
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repeats), and full mutation (1200 CGG repeats) (Fu et
al. 1991). Full-mutation alleles are disease causing,
whereas premutation alleles are not associated with clin-
ical symptoms but can undergo expansion to the full
mutation on transmission from mothers to offspring.
Because of this, prenatal testing in premutation or full-
mutation carriers should be offered in every pregnancy.
In the presence of the full mutation, the CpG island at
the 5′ of the FMR1 gene is hypermethylated, and the
transcription of the gene is shut down (Oberle´ et al.
1991; Pieretti et al. 1991).
The clinical features of males with the full mutation
are mental retardation, long face, large ears, prominent
jaw, postpubertal macroorchidism, strabismus, mitral-
valve prolapse, hyperactivity, and autistic behavior. Sim-
ilar, but milder, clinical features have been reported in
∼50%–70% of females heterozygous for the full mu-
tation (Rousseau et al. 1991; de Vries et al. 1996). Fe-
males who are premutation carriers have a 50% risk in
each pregnancy of transmitting the abnormal allele to
the offspring. The risks of expansion of a premutation
allele to the full mutation in the offspring have been
calculated on the basis of premutation repeat size and
have been summarized elsewhere (Warren and Nelson
1994; Nolin et al. 1996). The likelihood of repeat in-
stability increases with increasing repeat number. There
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Table 1
Number of Premutation Carriers
for Each Range of the Number
of CGG Repeats
CGG-Repeat Range
No. (%)
of Women
( )np 207
50–54 80 (39)
55–60 62 (30)
61–65 15 (7.2)
66–70 25 (12)
71–75 4 (1.9)
76–80 9 (4.3)
81–200 9 (4.3)
1200 3 (1.5)
is no expansion of the premutation allele to the full
mutation if it is transmitted to the offspring by males
(Oberle´ et al. 1991).
Premutation (154 repeats) carriers can be detected
only by direct molecular analysis of the FMR1 gene
repeat number, because they lack abnormal clinical fea-
tures. The prevalence of premutation carriers has been
found previously to be between 1:152 and 1:259
(Rousseau et al. 1995; Murray et al. 1997; Ryyna¨nen
et al. 1999; Pesso et al. 2000).
In a retrospective study performed by Rousseau et al.
(1995), the prevalence of premutation allele (154 re-
peats) carriers was found to be 1:259, and a meta-
analysis of five studies carried out by Murray et al.
(1997) established a premutation allele frequency of 1:
273. A smaller prospective study found a carrier fre-
quency of 1:246 for alleles with 160 repeats among
1,477 pregnant women tested for the fragile-X pre-
mutation in the Finnish population (Ryyna¨nen et al.
1999), and, in a comprehensive study conducted by
Pesso et al. (2000), the premutation carrier frequency
among Israeli women was found to be 1:70 for alleles
with 52 or more repeats and 1:152 for alleles with
154 repeats.
The aim of the present study was to evaluate the
effectiveness of a fragile-X carrier–screening program,
by studying the FMR1 gene CGG-repeat size and the
pregnancy outcome in the premutation and full-muta-
tion carriers in a group of 14,334 Israeli women of
child-bearing age from different ethnic groups and with
no family history of mental retardation.
Subjects and Methods
Between January 1, 1992, and October 31, 2000, a total
of 14,334 preconceptional or pregnant women were
tested at the Rabin Medical Center, Israel. They applied
for testing on their own initiative or on the advice of
their physician, on a self-pay basis. They each completed
a questionnaire to ascertain any family history of mental
retardation, and all women with such a family history
were excluded from the study. The ethnic origins of the
women screened were established by randomly sampling
the data from 1 out of every group of 10 consecutive
women each year between 1995 and 2000. Details about
the women during the years 1992–1994 were missing,
so we assumed the same ethnic distribution as for the
other years.
All the women who were found to be carriers of pre-
mutation alleles were offered genetic counseling. Those
who were already pregnant, and the preconceptional
women in the event of their becoming pregnant, were
provided with information about prenatal diagnosis by
amniotic-fluid analysis or chorionic villus sampling
(CVS), which would be financed by the Israeli Ministry
of Health.
We performed Southern blotting to ascertain the pres-
ence of normal, premutation (intermediate), or full-mu-
tation alleles (Rousseau et al. 1991). In those women
who were suspected carriers of premutation alleles, we
performed PCR analysis (Brown et al. 1993) to deter-
mine the exact number of CGG repeats in the abnormal
allele.
A cost-benefit study was recently carried out to ex-
amine whether, from a financial point of view, a screen-
ing program for fragile-X carrier status of the entire
female population of Israel is justified. This is described
in the Appendix.
Results
Among 14,334 normal healthy women screened for
FMR1 allelic expansion, we found 207 carriers of an
allele with 150 repeats, representing a prevalence of 1:
69 (confidence interval [CI] 1:62 to 1:83). When taking
55 CGG repeats as the lower limit for premutation-car-
rier status, the prevalence of such carriers was 1:113
(CI 1:96 to 1:136) (127 women). Three women were
found to carry the fully mutated allele. Table 1 details
the number of premutation carriers for each range of
the number of CGG repeats.
Of the women in the premutation/full-mutation car-
rier group, 173 were pregnant. Of these, 2 had mis-
carriages, 14 refused prenatal diagnosis, 16 had either
two pregnancies each (8 women) or twins (8 women),
and 2 had three pregnancies each, so that out of the
total of 193 pregnancies, 177 (91.7%) prenatal diag-
nosis procedures were performed (fig. 1).
Table 2 details the transmission of the FMR1 allele
to the fetus. In 90 pregnancies (50.8%), the allele con-
taining 150 repeats was transmitted, and 5 of these
expanded to the full mutation.
Figure 2 shows the results of prenatal diagnosis in
the group of fetuses with expansion of the abnormal
allele, according to the maternal premutation allele size.
There were 30 fetuses (16.9%) in which expansion oc-
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Figure 1 Flowchart of fragile-X screening results
Table 2
Transmission of FMR1 from Mother to Fetus
MATERNAL
REPEAT
NUMBER
IN
ABNORMAL
ALLELE
FETAL ALLELES
Non-Premutation
Allele
Transmitted
(!50 Repeats)
Premutation
Allele
Transmitted
(50–200 Repeats)
Full
Mutation
Allele
Transmitted
(1200 Repeats)
50–55 36 39 0
56–60 22 22 0
61–65 7 8 0
66–70 10 10 2
71–75 2 3 0
76–80 3 2 1
81–200 6 1 1
1200 2 0 1
Total 87 85 5
curred, 5 of which (16.7%) had an expansion to the
full mutation. All these five pregnancies were terminated
after confirmation of the prenatal diagnosis. No full
mutation was found in the fetuses of mothers with !70
CGG repeats.
In Israel, there are many diverse ethnic groups in a
relatively small population. Table 3 depicts the ethnic
distribution among the women screened and among the
premutation carriers. There were no ethnic differences
among premutation carriers, compared with the general
population, and no statistically significant differences
were found between any of the groups studied.
Figure 3 shows the cost-benefit analysis of running a
screening program. The financial analysis concluded
that the cut-off point for the cost of lifetime care of
a mentally retarded person is approximately U.S.
$350,000, so that if the cost in Israel is higher than this
amount, the screening program is financially worth-
while. As described in the Appendix, the estimated cost
of lifetime care for a mentally retarded person in Israel
is $680,000, which is well above the cut-off point
calculated.
Discussion
To date, there have been only a few reports of the es-
timated frequency of premutation allele carriers in the
general population (Rousseau et al. 1995; Murray et al.
1997; Ryyna¨nen et al. 1999; Pesso et al. 2000). A meta-
analysis of five studies established a premutation allele
frequency of 1:273 (Murray et al. 1997). In the retro-
spective study performed by Rousseau et al. (1995), a
total of 10,624 unselected women were evaluated and
the prevalence of premutation allele carriers (154 re-
peats) was found to be 1:259. Haplotype analysis of
polymorphic markers in the vicinity of the FMR1 gene
in this study showed a strong association of themutation
with one specific haplotype, especially among individ-
uals of French Canadian origin. It was suggested that
the founder effect was partly responsible for the high
carrier frequency found in this population. In a com-
prehensive study conducted by Pesso et al. (2000), the
premutation carrier frequency among Israeli womenwas
found to be 1:70 for alleles with 52 repeats and 1:
152 for alleles with 154 repeats. A smaller prospective
study found a carrier frequency of 1:246 for alleles with
160 repeats, among 1,477 pregnant women tested for
the fragile-X premutation in the Finnish population
(Ryyna¨nen et al. 1999). Our findings of a carrier fre-
quency of 1:113 for women with 154 repeats and 1:
220 for women with 160 repeats are comparable (table
4).
Fragile-X syndrome has been reported in both white
and black populations (Schwartz et al. 1988). In Israel,
among patients with fragile X, overrepresentation of
families of Tunisian Jewish origin has been described;
all of these share a common haplotype that lacks AGG
interruptions (Dar et al. 1995; Falik-Zaccai et al. 1997).
Conversely, however, no common founder haplotype
was detected in the Ashkenazi Jewish patients with frag-
ile-X syndrome (Pesso et al. 1997). In the present study,
the ethnic distribution of the premutation carriers was
found to be similar to that in the general population.
An extremely important part of any genetic screening
program is the availability of appropriate genetic coun-
seling. If a premutation carrier is identified, prenatal
diagnosis should be offered not only to the individual
carrier but also to any relatives who might be at risk,
in order to identify fetuses carrying an expansion of the
premutation to the full mutation. Therefore, the benefits
of undergoing the screening test are not limited to the
woman’s current pregnancy (i.e., the one during which
she was tested) but are also relevant for all her subse-
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Figure 2 Maternal allele expansion in the fetus
quent pregnancies and those of any carrier relatives who
were identified through her. No specific treatment exists
for this condition, but it is preventable by termination
of affected pregnancies.
There is no clear distinction between normal and pre-
mutation alleles; the alleles with 45–60 CGG repeats
are considered to be a “gray zone” because of their
ability to undergo expansion on transmission to the
fetus. In previous studies, instability in the transmission
of the gray-zone alleles has been observed in 25% of
alleles with 50–60 repeats but in !8% of those with
40–49 repeats (Nolin et al. 1996). No expansion of the
premutation to the full mutation has been described for
alleles containing !59 repeats (Sherman et al. 1994;
Nolin et al. 1996), and, in the present study, there was
no expansion of the premutation to the full mutation
for alleles containing !70 repeats. Similar results were
found by Ryyna¨nen et al. (1999) and Pesso et al. (2000)
(table 4). Carriers of a low borderline allele size should
be reassured that the risk for having a child with fragile-
X syndrome is extremely low.
As already mentioned, it is difficult to interpret the
significance of DNA test results showing CGG repeat
numbers in the range between normal and premutation.
In the present study, the smallest premutation allele size
that expanded to a full mutation was 70 repeats (table
4). Consequently, a cutoff point of 55 (or even 60) re-
peats can be considered as safe for making a decision
about the need for prenatal testing. It has been estimated
that only three invasive tests (CVS or amniocentesis) are
needed to detect one full-mutation case when prenatal
fetal evaluation is offered to women with 60 CGG
repeats (Murray et al. 1997).
In 2000, we published our results regarding selective
transmission of the premutation allele from carrier fe-
males to their fetuses (Drasinover et al. 2000). Among
the first 10,587 women studied, we found a significant
increase in the transmission of the abnormal allele by
mothers who had 51–60 repeats, but we found no in-
crease in transmission by mothers with 161 repeats.
Interestingly, with the addition of a further 3,747
women, this has been found not to be the case, and the
transmission of each allele was approximately equal.
The numbers are shown in table 2.
Until now, broad population screening for fragile-X
syndrome has not been recommended as a routine pol-
icy by any country, although guidelines for fragile-X
testing were proposed by the American College of Med-
ical Genetics (Park et al. 1994). It was recommended
that such testing should be performed in individuals
with mental retardation or learning disabilities, fetuses
of known carrier mothers, and individuals who have a
family history of fragile-X syndrome or undiagnosed
mental retardation and who are seeking reproductive
counseling. The main purpose of screening for fragile-
X syndrome is to reduce the incidence of the birth of
affected individuals. The feasibility of population
screening to detect premutation carriers has been dis-
cussed by several authors (Bonthron and Strain 1993;
Bundey andNorman 1993; Howard-Peebles et al. 1993;
Palomaki and Haddow 1993; Rousseau et al. 1994;
Finucane 1996; Spence et al. 1996; Ryyna¨nen et al.
1999; Tzeng et al. 1999; Wildhagen et al. 1999; Pesso
et al. 2000).
If the screening program is limited only to those
women with a known family history of fragile-X syn-
drome, several problems can occur. First, fragile-X syn-
drome can often appear as a new case in a family with
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Figure 3 Cost-effectiveness of the screening program
Table 3
Ethnic Distribution among Population Screened and among Fragile-X Premutation Carriers
POPULATION
NO. (%) IN ETHNIC GROUP
Ashkenazi
Jews
Iranian
and Iraqi
Jews
North
African
Jews
Balkan
Jews
Yemenite
Jews
Syrian
Jews
Non-Jewish
Israelis Othera Total
Population screened in:
1996 143.0 23.0 29.0 16.0 10.5 4.5 0.0 2.0 228.0
1997 165.5b 28.0 30.5 11.0 8.5 3.0 3.0 5.5 255.0
1998 88.0 24.0 15.5 9.5 10.0 .5 5.0 2.5 155.0
1999 96.0 23.0 21.5 6.0 7.5 3.0 1.0 2.0 160.0
2000 52.0 7.5 22.0 3.0 5.0 3.0 2.0 5.5 100.0
Total 544.5 (60.65) 105.5 (11.75) 118.5 (13.2) 45.5 (5.1) 41.5 (4.6) 14.0 (1.55) 11.0 (1.2) 17.5 (1.95) 898.0 (100)
Premutation carriersc 113.5b (54.85) 21.0 (10.15) 24.0 (11.6) 8.5 (4.1) 8.0 (3.85) 1.0 (.5) 0.0 (0) 6.0 (2.9) 207.0 (100)
a Including subjects from India, Georgia, and Kurdistan.
b Numbers denote the ethnic origin of the carrier according to the ethnic origins of each of her parents. If a woman has a parent from one ethnic group and
another from a different ethnic group, she adds 0.5 to each parental origin group.
c No data were available for 25 premutation carriers (12.05%).
no prior history of learning disabilities or mental re-
tardation. Second, there may be difficulties in contacting
all relatives at risk. These factors limit the sensitivity of
carrier detection by a proband-based approach. It was
estimated, by a microsimulation model, that at least
eight consecutive generations would need to be tested
in order to detect 90% of all premutation and full-
mutation carriers (Wildhagen et al. 1999). Such exten-
sive family tracing is technically difficult.
If screening of only those women who are mentally
retarded or who have learning disabilities is undertaken,
a significant number of the full-mutation carriers and
all of the premutation carriers would be missed. Fur-
thermore, it has been claimed that the frequency of pre-
mutation carriers was not higher among the women
with a family history of mental retardation (excluding
fragile-X syndrome) compared with the low-risk group
(Pesso et al. 2000). Any screening program that excludes
pregnant women without a known family history of
mental retardation will continue to miss a significant
number of fragile-X carriers.
Screening of preconceptional women will allow more
time for genetic counseling and decision making about
reproductive options in premutation carriers. On the
other hand, such screening is difficult in practice. There-
fore, the population of pregnant women appears to be
the most feasible group to screen, in spite of the ex-
pected anxiety regarding the outcome of the pregnancy
caused by a positive result.
Our survey included only those women who came for
testing on a self-pay basis. As a result, only women from
higher socioeconomic levels, who were able to afford
the cost of the test, were screened, and, therefore, these
women do not represent an unselected sample. The im-
pact of this bias on the results of the simulation and its
applicability to the general population are difficult to
assess.
Evaluation was undertaken recently comparing the
costs, effects, and benefits of prenatal, preconceptional,
and school-age carrier screening (Wildhagen et al.
1998). All three screening strategies were found to have
a positive cost-benefit ratio, but the authors found that
prenatal screening of pregnant women would detect
most carriers and would lead to the highest number of
avoided fragile-X syndrome cases, and they considered
that such screening was also the optimal strategy from
the economic point of view.
Our calculations of the costs and benefits show that,
from a financial point of view, a screening program is
worthwhile. Although the actual lifetime cost of caring
for a mentally retarded person in Israel is not accurately
known, some previous studies have estimated the cost
in other countries to be ∼$900,000 (Turner et al. 1986;
Nolin et al. 1991), and others have estimated it to be
between $1 million and $4 million (Finucane 1996).
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Table 4
Studies Evaluating Prenatal Fragile-X Screening in the Population of Childbearing Women
Study
No. of
Women
Tested
Premutation
Carrier
Frequency
Smallest
Repeat
Expanded
to Full
Mutation
No. of
Amniocenteses
No. of
Fetuses
with Full
Mutation
No. of
Pregnancy
Terminations
No. of
Fetal
Losses
Due to
CVS/ACa
Pesso et al. 2000 9,459 1:152b 62 108 9 9 0
Ryyna¨nen et al. 1999 1,477 1:246c 70 24 2d … …
Our study 14,334 1:113b 70 177 5 5 0
a CVS p chorionic villus sampling; AC p amniocentesis.
b Carrier frequency for women with 154 repeats.
c Carrier frequency for women with 160 repeats.
d One fetus showed mosaicism.
Since, as described above, the calculated cost of lifetime
care for a mentally retarded patient in Israel ($680,000)
is well above the cut-off point based on financial con-
siderations ($350,000), the screening program is
worthwhile.
The calculation based on (1) our data regarding the
prevalence of the carrier status of fragile-X syndrome
and the incidence of fetuses carrying the full mutation,
(2) the cost, adjusted for Israel, of lifetime care for a
retarded person, and (3) a 50% acceptance rate of the
screening program, shows that the expected net benefit
from running the program is ∼$5,500,000 per year (see
Appendix). The net benefit remains positive over a wide
range of acceptance rates. It is, therefore, clearly evident
that the results of the cost-benefit study, from a socio-
economic point of view, justify the financing, by public
funds, of a screening program in Israel for fragile-X
syndrome.
Finally, scarcity of data regarding the population fre-
quency of fragile-X premutation carriers and concerns
about the cost of screening have, so far, delayed decision
making. The high frequency of premutation carriers
found by screening in this and other studies, including
150,000 women overall, points clearly to the appro-
priateness of population screening. Because of the high
prevalence of fragile-X syndrome, the lack of treatment
for those suffering from it, and the cost-effectiveness of
the carrier-screening strategy, we propose to offer such
screening to all pregnant women to minimize or even
eliminate the risk of having a child with mental retar-
dation caused by this syndrome.
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Appendix
Cost-Effectiveness Analysis
By use of DATA 3.5 software (Treeage Software), a
model of a decision tree was constructed, in which the
decision junction was running versus not running a
screening program. For each possible event, whether the
decisions were made by the target population (e.g., ac-
ceptance of each step of screening, termination of a preg-
nancy) or by the results (carrier status, affected fetus, or
miscarriage), a separate branch was made and given a
probability for that event. The whole tree consisted of
132 branches representing every possible sequence of
events. For each such sequence of events, a “payoff”
was calculated in financial terms: the costs were assessed
for each step of the screening program, including ad-
ministration and publicity, blood tests, molecular-biol-
ogy studies (Southern blotting and PCR), genetic coun-
seling, invasive procedures for prenatal diagnosis (in case
a screened woman was found to be a carrier), the costs
of fetal loss (miscarriage) occurring as a result of invasive
procedures, if taken, and the expenses for the screened
woman (such as travel costs and loss of work time).
Benefits taken into consideration were (1) the cost of the
lifetime care of a mentally retarded person and (2) the
costs saved by not performing additional fetal testing on
women who would be undergoing such testing anyway,
because they were at risk of having a fetus with trisomy
21 (table A1).
Table A2 shows the probabilities. The rates of rejec-
tion [P1] or acceptance [#(P1)] of the screening program
are based on the rates of rejection or acceptance of other
prenatal screening programs that are well established in
Israel (Ginsberg et al. 1994, 1998). The rates, among
the Israeli population, of having [#(P2)] or not having
[P2] the full fragile-X mutation and of being a carrier
[#(P3)] or not being a carrier [P3] of the full fragile-X
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Table A1
Costs and Benefits
Factor
Benefit
($) Symbol
Publicity for each person in the target population 1 C0
DNA testing and expenses for tested woman 110 C1
Amniocentesis and karyotype 155 C2
DNA testing of the fetus 98 C3
Genetic counseling following fetal diagnosis 51 C4
Iatrogenic abortion 658 C5
Cost of genetic counseling following fetal diagnosis 128 C6
Cost of abortion (iatrogenic or therapeutic) 483 C7
Cost of genetic counseling following diagnosis of carrier status 27 C8
Not running a screening program 0 C9
Birth of a nonretarded child 0 B1
Lifetime care of a mentally retarded person 680,000 B2
Lost fetuses (due to either iatrogenic abortion or termination
of a nonretarded female with the full fragile-X mutation) 36,500 B3
mutation are based on our current study, which includes
14,334 women. The rates of acceptance [#(P4)] or re-
jection [P4] of genetic counseling among carriers is taken
from our current study and from a recent study carried
out in Finland (Ryyna¨nen et al. 1999). The rates of the
fetus having [#(P5)] or not having [P5] the full fragile-
X mutation, where the mother is a carrier, are taken
from our own data. The rates of performing [#(P6)] or
rejecting [P6] prenatal diagnosis among carrier mothers
are based on the data from our current study. The rate
of finding the full fragile-X mutation in the diagnosis of
the fetus [#(P7,P8,P9,P10)] is based on the data from
our current study.
The rate of iatrogenic abortion following prenatal di-
agnosis is based on the data from a study analyzing the
cost-effectiveness of a screening program in the Neth-
erlands (Wildhagen et al. 1998) and on a personal com-
munication (R. Sharony, Genetics Institute, Meir Hos-
pital, Sapir Medical Center, Kfar Saba, Israel). We took
the rates of finding somatic-chromosome abnormalities
[P9] and sex-chromosome abnormalities [P10] in the fe-
tus from the data from a previous analysis in the Neth-
erlands (Wildhagen et al. 1998). Finding a normal fetus
following prenatal diagnosis [P7] is the complementary
probability of the consequences of prenatal diagnosis.
Rates of termination of pregnancy of fetuses with a so-
matic-chromosome abnormality [#(P11)] or a sex-chro-
mosome abnormality [#(P12)] and of rejection of ter-
mination of pregnancy in these cases [P11 and P12] are
based on past experience in Israel and on data from the
Netherlands (Wildhagen et al. 1998). Rates of termi-
nation of pregnancy [#(P13)] or rejection of termination
of pregnancy [P13] of a fetus with the full fragile-X
mutation are based on the data of the current study, on
past experience in Israel, and on data from the Neth-
erlands (Wildhagen et al. 1998).
We followed the rates used by Wildhagen et al. (1998)
in their cost-effectiveness analysis for males [P14] and
females [#(P14)] among patients with the full fragile-X
mutation, for mentally retarded males [P15] and females
[P16] with the full fragile-X mutation, and for non–
mentally retarded males [#(P15)] and females [#(P16)]
with the full fragile-Xmutation. The rate of second preg-
nancies [P17] comes from statistical data in Israel (Cen-
tral Bureau of Statistics 1999). The rates of rejection
[P18] or acceptance [#(P18)] of a screening program by
a woman in her second pregnancy who had rejected such
a program in the past is our tentative assumption.
The costs of publicity and distribution of information
about the screening program are based on the costs that
the Israeli Ministry of Health allocates for various
screening, immunization, or early-interventionprograms
and is for each person in the target population (G. Gins-
berg, Israeli Ministry of Health, personal communica-
tion). The cost of DNA testing of the woman [C1] con-
sists of the current price charged for the test in Israel
plus her expenses, on the basis of the calculations made
for a cost-benefit analysis for prenatal diagnosis for cys-
tic fibrosis in Israel (Ginsberg et al. 1994), and was cor-
rected according to the change in the Consumer Price
Index. The cost for amniocentesis and karyotype for
fragile-X carriers [C2] is based on the cost of these tests
in Israel, corrected for the number of pregnant women
35 years old (Central Bureau of Statistics 1999) and
for the number of women !35 years old with a positive
triple test for trisomy 21 (Herman et al. 1997). The cost
of the DNA test of the fetus [C3] is the same as the cost
for this test in the screened woman. The cost of genetic
counseling following the fetal diagnosis [C4] is calcu-
lated according to the cost for this in Israel and was
corrected for the number of pregnant women35 years
old (Central Bureau of Statistics 1999) and for the num-
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Table A2
Probabilities
Event Probability Symbol
Rejection of screening program .5 P1
Acceptance of screening program .5 #(P1)
Not finding the full fragile-X mutation among women who rejected screening 2,866/2,867 P2
Finding the full fragile-X mutation among women who rejected screening 1/2,867 #(P2)
Not being a carrier among women who accepted screening 112/113 P3
Being a carrier among women who accepted screening 1/113 #(P3)
Rejection of genetic counseling among carriers 0 P4
Acceptance of genetic counseling among carriers 1 #(P4)
A fetus that does not have the full fragile-X mutation where the mother is a carrier .958 P5
A fetus that does have the full fragile-X mutation where the mother is a carrier .042 #(P5)
Rejection of fetal diagnosis where the mother is a carrier .05 P6
Performing fetal diagnosis where the mother is a carrier .95 #(P6)
Finding normal fetus following fetal diagnosis .944 P7
Iatrogenic abortion following fetal diagnosis .01 P8
Finding somatic chromosome abnormality in the fetus at prenatal diagnosis .002 P9
Finding sex chromosome abnormality in the fetus at prenatal diagnosis .002 P10
Finding the full fragile-X mutation in the fetus at prenatal diagnosis .042 #(P7,P8,P9,P10)
Rejection of termination of pregnancy where there is a somatic-chromosome abnormality in the fetus 0 P11
Termination of pregnancy where there is a somatic-chromosome abnormality in the fetus 1 #(P11)
Rejection of termination of pregnancy where there is a sex-chromosome abnormality in the fetus 0 P12
Termination of pregnancy where there is a sex-chromosome abnormality in the fetus 1 #(P12)
Rejection of termination of pregnancy where the fetus has the full fragile-X mutation 0 P13
Termination of pregnancy where the fetus has the full fragile-X mutation 1 #(P13)
Fetus with the full fragile-X mutation is male .5 P14
Fetus with the full fragile-X mutation is female .5 #(P14)
Mentally retarded male with the full fragile-X mutation 1 P15
Nonretarded male with the full fragile-X mutation 0 #(P15)
Mentally retarded female with the full fragile-X mutation .59 P16
Nonretarded female with the full fragile-X mutation .41 #(P16)
Pregnancy is a second pregnancy .272 P17
Pregnancy is a first or third (or more) pregnancy .728 #(P17)
Rejection of screening in second pregnancy where this was rejected in the previous pregnancy 1 P18
Acceptance of screening in second pregnancy where this was rejected in the previous pregnancy 0 #(P18)
ber of women !35 years old with a positive triple test
for trisomy 21 (Herman et al. 1997). The cost of an
iatrogenic abortion [C5] is the cost of a day of in-hos-
pital stay multiplied by the average stay in hospital for
this condition (1.89 d) (Ginsberg et al. 1994) and is
derived from the Israeli Ministry of Health List of Prices
for the year 2000. Parental costs, including traveling
expenses and loss of work time, the cost of genetic coun-
seling after the diagnosis of carrier status [C8], the cost
of genetic counseling after fetal diagnosis [C6], and the
cost of iatrogenic or therapeutic abortion [C7] were de-
rived from a cost-benefit analysis for prenatal diagnosis
for cystic fibrosis in Israel (Ginsberg et al. 1994) and
were corrected according to the change in the Consumer
Price Index. The cost of not running a screening program
[C9] is, by definition, zero. However, this is not the same
as the cost per woman in the target population who does
not accept screening, because of the cost of the publicity
of the screening program, which is constant whether or
not the woman accepts screening.
The benefit per birth of an unaffected (nonretarded)
child is, by definition, zero. However, the benefit of the
prevention of the birth of each mentally retarded indi-
vidual [B2], whether the retardation is due to the full
fragile-X mutation or to other genetic causes, is the cost
of the lifetime care of a mentally retarded person in
Israel. Unfortunately, there is no information, or even
an official estimate, of the cost of the lifetime care of a
mentally retarded person in Israel. To bypass thismissing
information, we used the cost of the lifetime care of a
male with the full fragile-X mutation in the Netherlands
(Wildhagen et al. 1998), where this was calculated to
be $957,000. This cost was corrected for Israel, accord-
ing to the ratio between the gross national product per
capita in Israel and that in the Netherlands in 1999,
which was 0.71 (P. Bachrach, Royal Netherlands Em-
bassy in Israel, personal communication), and we thus
arrived at an estimate of $680,000 for the lifetime cost
of caring for a mentally retarded person in Israel.
The rationale for using the costs from another country
(the Netherlands) is that that country is similar in size
to Israel and has a comparable system of social medicine.
More importantly, the figures are only rough estimates
that allowed us to run a sensitivity analysis and to find
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a cut-off point for Israel, so that if the cost of the lifetime
care of a mentally retarded person in Israel is above this
point, then the screening program will have a favorable
cost-saving balance. Having arrived at this cut-off point,
this figure can now be adjusted to take into consideration
the existing information about the cost of the lifetime
care of a mentally retarded person in Israel. The cal-
culation—based on our data regarding the prevalence of
the carrier status of fragile X, the incidence of fetuses
carrying the full mutation, the cost of lifetime care for
a retarded person adjusted for Israel, and the assumption
of a 50% acceptance rate of the screening program—
shows that the expected net benefit from running the
program is ∼$5,500,000 per year.
We used the cost of the lifetime care of a male with
the full fragile-X mutation in the Netherlands, since, in
the way that the calculations of cost-effectiveness were
made, correction has already been made for the
non–mentally retarded females with the full fragile-X
mutation. It should be mentioned that the value of B2
has a minus sign, since, in the way the tree is constructed,
B2 represents the expense when a sequence of events
leads to the birth of a retarded individual (when the birth
of a nonretarded individual is given the benefit B1, which
is zero).
We decided to present the cost of the loss of normal
fetuses, whether due to iatrogenic abortion or to the
termination of a nonretarded female with the full fragile-
X mutation, on the benefit side, since these are events
that are not controlled by the physician, and marked it
as B3. However, since it is a loss and not a benefit, it
has a minus sign. The costs for this are based on cal-
culations made in a previously published cost-benefit
analysis of prenatal screening for cystic fibrosis in Israel
(Ginsberg et al. 1994) and are corrected for the change,
since the original calculations were made, in the gross
national product and the average income. Nevertheless,
the current trend in cost-benefit analysis regarding pre-
natal diagnosis is to give the loss of fetuses a value of
zero.
A guideline we used for the whole analysis was to
remain as conservative as possible in deciding which
costs and benefits to take into account; for example, we
avoided giving a value of zero to the cost of lost fetuses.
However, we did not take into account some “vertical”
savings (such as not needing to screen women in their
third or later pregnancy), as well as some expected “hor-
izontal” savings, such as screening of female relatives of
women found to be carriers during the first years of
running the program.
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